← Back to screener

CG Oncology, Inc. CGON

Rank #1906 · Nasdaq · $5.7B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
39.1
P/E
-117.4
P/B
-73.43
ROE
62.6%
Op. Margin
-27180.9%
Debt Ratio
-28%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -117.4x, P/B -73.43x. Ranks in the top 83% of the universe.

Profitability ★★☆☆☆
Average

ROE 62.6%. Ranks in the top 52% of the universe.

Safety ★★★★★
Excellent

Debt ratio -28%. Ranks in the top 7% of the universe. Under 100% is generally considered a safe level.

Growth ★★☆☆☆
Weak

Revenue growth of 0.0% year over year. Ranks in the top 64% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2024$0.0B$-0.1B$-0.0B$-0.1B-27180.9-19
2025$0.0B$-0.1B$-0.0B$-0.1B-27180.9-28

← See the full screener